Compare Abbott Laboratories (ABT) vs Cincinnati Financial Corporation (CINF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Cincinnati Financial Corporation — how do they compare? Abbott Laboratories trades at $109.69 (market cap $187.95B), while Cincinnati Financial Corporation trades at $173.45 (market cap $26.68B). The key difference: Abbott Laboratories is far larger — about 7× Cincinnati Financial Corporation's market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | CINF | |
|---|---|---|
Market Cap | $187.95B | $26.68B |
Sector | Health | Financials |
52-Week High | $136.62 | $192.03 |
52-Week Low | $82.57 | $149.79 |
Enterprise Value | $214.96B | $25.80B |
Dividend Yield | 2.32% | 2.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
Cincinnati Financial (CINF) trades at $176.86, down 1.22% on the day, with a bearish technical signal but strong fundamentals including a P/E of 8.35 and ROE of 21.48%. Recent Q2 2026 earnings missed estimates at $1.43 per share versus $1.84 expected, though revenue grew year-over-year. The company maintains robust cash flow, with 2025 operating cash flow at $3.11 billion, and a consistent dividend history, including a recent $0.94 payout.
Outlook is mixed: valuation appears attractive with analyst consensus price target of $195, but near-term headwinds include catastrophe losses and commercial lines weakness. Long-term growth is supported by premium expansion and investment income, though investors face risks from underwriting volatility and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →
